Stay updated on HepTcell Immunotherapy in Inactive CHB Clinical Trial
Sign up to get notified when there's something new on the HepTcell Immunotherapy in Inactive CHB Clinical Trial page.

Latest updates to the HepTcell Immunotherapy in Inactive CHB Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe Locations section is updated to add regional entries (California, Alberta, Ontario, Missouri, Oklahoma) and remove the separate location groupings, with the revision updated to v3.3.3.SummaryDifference0.6%

- Check16 days agoChange DetectedResults-related updates were added, including 'Results First Posted (Estimated)' on 2025-12-04 and associated results submission milestones. New and updated outcomes are listed, such as virologic response, serologic clearance of HBsAg and HBV DNA on Day 169, and changes in HBV markers and immune responses.SummaryDifference2%

- Check30 days agoChange DetectedAdded Revision: v3.3.2 label on the page, replacing Revision: v3.2.0. This appears to be a system update and does not modify study details or other user-visible content.SummaryDifference0.1%

- Check38 days agoChange DetectedRemoved the site-wide notice about funding-related delays and operating status. The page now presents only trial-specific details and status.SummaryDifference0.4%

- Check60 days agoChange DetectedThe new screenshot shows minor adjustments to layout and styling without altering core study details such as the title, status, eligibility criteria, or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check81 days agoChange DetectedCore content updated: a government funding and operating status notice has been added and the version updated to v3.2.0; the prior v3.1.0 tag was removed.SummaryDifference5%

Stay in the know with updates to HepTcell Immunotherapy in Inactive CHB Clinical Trial
Enter your email address, and we'll notify you when there's something new on the HepTcell Immunotherapy in Inactive CHB Clinical Trial page.